ALXO Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: FN Media Group LLC - Mentions: ONCY ERAS IMRX PRLD

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

15 days ago - By: ALX Oncology

ALX Oncology to Present at Upcoming Investor Conferences

a month ago - By: Benzinga

Examining the Future: ALX Oncology Holdings's Earnings Outlook

4 months ago - By: Benzinga

ALX Oncology Holdings's Earnings: A Preview

15 days ago - By: ALX Oncology

ALX Oncology to Present at Upcoming Investor Conferences

26 days ago - By: ALX Oncology

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

26 days ago - By: ALX Oncology

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: ALX Oncology

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

a month ago - By: ALX Oncology

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

a month ago - By: ALX Oncology

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

2 months ago - By: ALX Oncology

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

2 months ago - By: ALX Oncology

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

3 months ago - By: ALX Oncology

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

3 months ago - By: ALX Oncology

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

3 months ago - By: ALX Oncology

ALX Oncology to Participate in Upcoming Investor Conferences in September

3 months ago - By: ALX Oncology

ALX Oncology to Participate in Upcoming Investor Conferences in September

4 months ago - By: ALX Oncology

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

4 months ago - By: ALX Oncology

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: ALX Oncology

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: ALX Oncology

ALX ONCOLOGY HOLDINGS INC (ALXO) Stock News

ALXO Latest News, Press Relases and Analysis

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

ALX Oncology to Present at Upcoming Investor Conferences

Examining the Future: ALX Oncology Holdings's Earnings Outlook

ALX Oncology Holdings's Earnings: A Preview

ALX Oncology to Present at Upcoming Investor Conferences

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

ALX Oncology to Participate in Upcoming Investor Conferences in September

ALX Oncology to Participate in Upcoming Investor Conferences in September

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025